Table 2.
Tumor Responses in the Lenvatinib Alone Group (Monotherapy%) and the Lenvatinib Plus Anti-PD-1 Group (Combination Therapy%) by Response Evaluation Criteria in Solid Tumors v1.1 Before and After SIPTW Adjustment
| Best Overall Response | Unweighted Study Population | Weighted Study Population After SIPTW | ||||||
|---|---|---|---|---|---|---|---|---|
| Monotherapy (n=140) | Combination Therapy (n=70) | P-value | SMD value | Monotherapy (n=140.13) | Combination Therapy (n=69.68) | P-value | SMD value | |
| CR | 0 (0.0%) | 0 (0.0%) | NA | NA | 0 (0.0%) | 0 (0.0%) | NA | NA |
| PR | 17 (12.1%) | 18 (25.7%) | 0.013 | 0.417 | 17.5 (12.5%) | 17.0 (24.5%) | 0.043 | 0.313 |
| SD | 72 (51.4%) | 38 (54.3%) | 0.696 | <0.001 | 69.9 (49.9%) | 37.2 (53.6%) | 0.655 | 0.075 |
| PD | 51 (36.4%) | 14 (20.0%) | 0.023 | 0.371 | 52.1 (37.1%) | 11.1 (15.9%) | 0.002 | 0.494 |
| ORR | 17 (12.1%) | 18 (25.7%) | 0.013 | 0.417 | 17.5 (12.5%) | 17.0 (24.5%) | 0.043 | 0.313 |
| DCR | 89 (63.6%) | 56 (80.0%) | 0.023 | 0.371 | 87.5 (62.4%) | 54.3 (78.1%) | 0.046 | 0.35 |
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.